Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-09-13
2011-10-18
Switzer, Juliet (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200
Reexamination Certificate
active
08039211
ABSTRACT:
The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
REFERENCES:
patent: WO 94/29469 (1994-12-01), None
patent: WO 97/00957 (1997-01-01), None
Zaman et al. PNAS USA 91:8822-8826, Sep. 1994.
Cole et al. GenBank Accession L05628; GI: 292332; Mar. 29, 1993.
Hacker et al. Gut 1997, vol. 40: 623-627.
Leucentini. The Scientist, Dec. 20, 2004, p. 20.
Mummidi et al. The Journal of Biological Chemistry, vol. 275, No. 25, 18946-18961, 2000.
Juppner et al. Bone. vol. 17, No. 2, Supplement, p. 39S-42S, 1995.
Rund et al. (Adv Exp Med Biol. 1999;457:71-5).
Cole et al. (Science, vol. 258, Dec. 1992, pp. 1650-1654).
Anderson, “Human Gene Therapy”,Science, 256:808-813 (1992).
Bakos et al., “Functional Multidrug Resistance Protein (MRP1) Lacking the N-Terminal Transmembrane Domain,”Journal of Biological Chemistry, 273(27):32167-32175 (1998).
Berry et al., “A Prototype Computer System for De Novo Protein Design,”Biochemical Society Transactions, 2(4):1033-1036 (1994).
Bertz et al., “Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions,”Clinical Pharmacokinetics, 32(3):210-258 (1997).
Borst et al., “The Multidrug Resistance Protein Family,”Biochimica et Biophysica Acta, 1461:347-357 (1999).
Borst et al., “A Family of Drug Transporters: The Multidrug Resistance-Associated Proteins,”Journal of National Cancer Institute, 92(16):1295-1302 (2000).
Campling et al., “Expression of theMRPandMDRIMultidrug Resistance Genes in Small Cell Lung Cancer,”Clinical Cancer Research, 3(1):115-122 (1997).
Chow et al. “Rising Incidence of Renal Cell Cancer in the United States,”JAMA, 281(17):1628-1631 (1999).
Cole et al., “Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP,”BioEssays, 20(11):931-940 (1998).
Cole et al., “Pharmacological Characterization of Multidrug Resistant MRP-transfected Human Tumor Cells,”Cancer Research, 54:5902-5910 (1994).
Database EMBL Online EBI; Seq ID No. 75, Database Accession No. AC026452, XP002217455 abstract (2000).
Database EMBL Online EBI; Database Accesion No. AC026452, Doe Joint Genome Institute: “Sequencing of Human Chromosome 16” XP002241553 for SEQ ID Nos. 171 and 172 Abstract (2000).
D'Hondt et al., “Retrovirus-Mediated Gene Transfer of the Multidrug Resistance-Associated Protein (MRP) cDNA Protects Cells from Chemotherapeutic Agents,”Human Gene Therapy, 8(15):1745-1751 (1997).
Dörner et al., “The Synthesis of Peptidomimetic Combinatorial Libraries Through Successive Amide Alkylations,”Bioorganic and Medicinial Chemistry, 4(5):709-715 (1996).
Engel et al., “Prediction of CYP2D6-Mediated Polymorphic Drug Metabolism (Sparteine Type) Based on In Vitro Investigations,”Journal of Chromatography B: Biomedical Applications, 678:93-103 (1996).
Evers et al., “Inhibitory Effect of the Reversal Agaents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MR2-Mediated Transport,”British Journal of Cancer, 83(3):366-374 (2000).
Fassina et al., “Identification of Interactive Sites of Proteins and Protein Receptors by Computer-Assisted Searches for Complementary Peptide Sequences,”Immunomethods, 5:114-120 (1994).
Filipits et al., “Immunocytochemical Detection of the Multidrug Resistance-Associated Protein and P-Glycoprotein In Acute Myeloid Leukemia: Impact of Antibodies, Sample Source and Disease Status,”Leukemia, 11(7):1073-1077 (1997).
Flens et al., “Immunochemical Detection of the Multidrug Resistance-Associated Protein MRP In Human Multidrug-Resistant Tumor Cells by Monoclonal Antibodies,”Cancer Research, 54(17):4557-4563 (1994).
Galfrè et al., “Preparation of Monoclonal Antibodies: Strategies and Procedures,”Methods in Enzymology, 73:3-46 (1981).
Giordano et al., “Intracoronary Gene Transfer of Fibroblast Growth Factor-5 Increases Blood Flow and Contractile Function in an Ischemic Region of the Heart,”Nature Medicine, 2(5):534-539 (1996).
Grant et al., “Analysis of the Intron-Exon Organization of the Human Multidrug-Resistance Protein Gene (MRP) and Alternative Splicing of Its mRNA,”Genomics, 45(2):368-378 (1997).
Heath et al., Hypertension, Diuretics, and Antihypertensive Medications as Possible Risk Factors for Renal Cell Cancer,American Journal of Epidemiology, 145(7):607-613 (1997).
Heijn et al., “Anthracyclines Modulate Multidrug Resistance Protein (MRP) Mediated Organic Anion Transport,”Biochimica et Biophysica Acta, 1326: 12-22 (1997).
Hipfner et al., “Monoclonal Antibodies that Inhibit the Transport Function of the 190-kDa Multidrug Restistance Protein, MRP,”Journal of Biological Chemistry, 274(22):15420-15426 (1999).
Hipfner et al., “Detection of the Mr190,000 Multidrug Resistance Protein, MRP, with Monoclonal Antibodies,”Cancer Research, 54(22):5788-5792, 1994.
Hipfner et al., “Membrane Topology of the Multidrug Resistance Protein (MRP),”Journal of Biological Chemistry, 272(38):23623-23630 (1997).
Hipfner et al. “Structural, Mechanistic and Clinical Aspects of MRP1,”Biochimica et Biophysica Acta, 1461:359-376 (1999).
Hoffman et al., “Rapid Protein Structure Classification Using One-Dimensional Structure Profiles on the Bioscan Parallel Computer,”CABIOS, 11(6):675-679 (1995).
Hrycyna et al., Mechanism of Action of Human P-glycoprotein ATPase Activity,Journal of Biological Chemistry, 273(27):16631-16634 (1998).
Isner et al, “Clinical Evidence of Angiogenesis After Arterial Gene Transfer of phVEGF165 in Patient With Ischaemic Limb,”Lancet, 348(10):370-374 (1996).
Jedlitschky et al., “ATP-Dependent Transport of Bilirubin Glucuronides by the Multidrug Resistance Protein MRP-1 and Its Hepatocyte Canalicular Isoform MRP2,”Biochemical Journal, 327:305-310 (1997).
Jounaïdi et al., “Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?,”Biochemical and Biophysical Research Communication, 221:466-470 (1996).
Klein et al., “An Inventory of the Human ABC Proteins,”Biochimica et Biophysica Acta, 1461:237-262 (1999).
Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature, 256:495-497 (1
Brinkmann Ulrich
Hoffmeyer Sven
Mornhinweg Esther
McCarter & English LLP
PGxHealth LLC
Switzer Juliet
LandOfFree
Polymorphisms in the human gene for the multidrug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphisms in the human gene for the multidrug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphisms in the human gene for the multidrug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278318